The companies said the tie-up lets researchers move AI-generated molecular sequences into synthesis, expression and testing, with GenScript delivering model-ready experimental data in as little as four days.
GenScript Biotech Corporation and Tamarind Bio said they have formed a strategic partnership to connect Tamarind Bio's AI-powered molecular design platform with GenScript's wet-lab validation capabilities, aiming to speed the path from computer-generated drug candidates to experimental evidence. The companies said researchers using Tamarind Bio will be able to submit AI-generated sequences and access GenScript's end-to-end services for synthesis, expression and testing through a single workflow, reducing manual handoffs and helping teams prioritize candidates faster. The partnership targets a discovery bottleneck emerging as AI sharply expands the number of potential molecules entering research pipelines while lab validation remains a constraint. GenScript said its wet-lab infrastructure can turn digital sequences into model-ready experimental data in as little as four days. Tamarind Bio said its no-code platform gives biologics and small molecule researchers access to more than 300 computational biology models. The companies said earlier validation could improve decision-making across therapeutics, cell and gene therapy, and industrial biotechnology.